期刊
JOURNAL OF HEPATOLOGY
卷 48, 期 1, 页码 28-34出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jhep.2007.07.026
关键词
hepatitis C treatment; insulin resistance; genotype 2 and 3 hepatitis C
资金
- NIDDK NIH HHS [DK98017] Funding Source: Medline
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056402] Funding Source: NIH RePORTER
Background/Aims: Obesity is associated with impaired treatment responses in chronic hepatitis C. The aim of this study was to determine the relationship between the insulin resistance frequently seen in obese subjects and sustained virological response to anti-viral therapy (SVR) in patients with genotype 2 or 3 infection. Methods: Eighty-two patients were studied; 59 received interferon/ribavirin while 23 received peg-interferon/ribavirin. Results: The overall SVR was (77%). Patients with a SVR had lower mean serum insulin (10.7 +/- 0.8 mu U/ml vs. 22.2 +/- 4.9; P = 0.03), fibrosis stage (1.9 +/- 0.1 vs. 2.7 +/- 0.3; P = 0.007) and insulin resistance measured by the homeostasis model (HOMA-IR) (2.5 +/- 0.2 vs. 6.1 +/- 1.5; P = 0.03). Age, gender, ethnicity, alcohol consumption, treatment regimen, viral load, portal activity and steatosis did not influence the SVR. By linear regression, body mass index (P < 0.001) and fibrosis stage (P < 0.001) were independently associated with HOMA-IR. After adjusting for fibrosis stage, patients with HOMA-IR of < 2 were 6.5 times more likely to achieve SVR than those with HOMA-IR >= 2. Conclusions: Even in treatment-responsive genotypes 2 and 3, high HOMA-IR is associated with a reduced response. Improving insulin sensitivity may be a useful adjunct to anti-viral therapy in these individuals. Crown copyright (c) 2007 Published by Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据